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researchers, and clinicians. Two focus groups containing eight to
ten patients who met the inclusion criteria for insomnia (diagno-
sis, history) were surveyed. A preliminary instrument containing
42 items (scale: 1 = not important at all to 5 = extremely impor-
tant), including demographic characteristics and co-morbidities,
was developed and then pretested in 14 additional patients prior
to validation testing. RESULTS: Currently, 109 patients have
participated in the testing of the instrument (mean age 50 + 11.5
years, 67.9% female). Principal components exploratory factor
analysis (KMO = 0.85) reduced the instrument to 17 items
(Cronbach á = 0.90) in 5 domains. Cronbach á for the 5 domains
(contentment, dosing ﬂexibility, outlook, value, and treatment
satisfaction) ranged from 0.73 to 0.86. Convergent and discrimi-
nant validity were assessed to determine scale acceptability for
further analysis. Goodness of ﬁt measures for the measurement
model (AMOS, version 7) were c2 = 50.8, df = 53, p = 0.559;
CFI = 1.00, GFI = 0.94, NFI = 0.92, RMSEA = 0.001, which
support the relationship between the data and the hypothesized
model. We anticipate recruiting more patients to ensure that the
data are consistent. CONCLUSION: Preliminary data from the
structural equation model revealed a 17-item instrument with 5
important domains (contentment with therapy, dosing ﬂexibility,
and outlook with respect to treatment satisfaction and value).
Further assessment and validation of the instrument is planned.
This novel instrument may provide greater knowledge regarding
the impact of psychological domains on treatment satisfaction
for patients with insomnia.
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OBJECTIVE: Multiple sclerosis (MS) is a chronic neurodegen-
erative disease which is the second most frequent cause of neu-
rological disability in young adults. The relapsing forms of the
disease are primarily treated with interferon beta or glatiramer
acetate. The aim of this study was to evaluate the level of satis-
faction of Spanish MS patients treated with the new formula-
tion of Avonex®, and whether this inﬂuences adherence.
METHODS: Data were obtained from the Global Adherence
Project, a multicenter open-label, post-marketing surveillance
study, performed in 17 centers in Spain. This included assessment
of the level of patient and neurologist satisfaction with the new
Avonex® formulation after 6 months of therapy. Two question-
naires were administered, one for patients and another for neu-
rologists. The study was approved by ethics committees and
patients signed informed consent. Descriptive statistical analyses
were performed. RESULTS: Of 257 patients included, 57
(22.2%) were treated with Avonex®; 55.4% of patients and
5.9% of neurologists were fully satisﬁed with the new formula-
tion. Most neurologists (88.3%) had intermediate satisfaction
scores. For patients and for neurologists, the most noteworthy
aspect of the change of formulation was the ease of use (73.2%
and 82.4%, respectively), followed by ease of storage (44.6%
and 29.4%), ease of injection (39.3% and 70.6%), less medica-
tion administered (25.0% and 11.8%) and for patients only,
better tolerability (8.9%). Adherence with Avonex® was 96.4%,
the highest among the therapies evaluated. CONCLUSION:
Both patients and neurologists were satisﬁed with Avonex® as
solution for injection. The most noteworthy aspect was the ease
of use. This seems to have a positive inﬂuence in the overall
patients’ adherence to the therapy.
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OBJECTIVE: Assess the types and number of health care pro-
fessionals seen by patients before diagnosis with dystonia and the
length of time from onset of symptoms. Describe the common
types of dystonias that are treated by the movement disorder
specialists and when appropriate, receive Botulinum Toxin Type
A treatment. METHODS: Patients with dystonia were asked to
complete a 19-question survey developed by the Canadian Move-
ment Disorders Survey Group. Questions included patient demo-
graphics, length of time from onset, number and types of
physicians seen, other diagnoses made, number treated with
Botulinum Toxin Type A and distance traveled. RESULTS: In this
interim analysis, 550 patients with dystonia were surveyed.
Majority of the patients were female (71%), traveling an average
of 99 km one-way. Most common dystonia diagnoses were
cervical dystonia (51%), hemifacial spasm (20%), and ble-
pharospasm (11%). Common diagnoses made prior to the dys-
tonia diagnoses were nerve/muscle problem (34%), stress/
psychological problem (39%), tremor (20%), ﬁbromyalgia
(19%), TMJ (16%), joint/tendon problem (15%) and spine
(11%). The average number of physicians seen before the dysto-
nia diagnosis was 3.2. Amongst these were family physician
(78%), neurologist (78%), movement disorder specialist (29%),
chiropractor (18%), eye care doctor (17%), neurosurgeon
(11%), and physiotherapist (15%). Most physicians who made
the dystonia diagnosis were neurologist (69%) and movement
disorder specialist (27%). The average time in years from onset
of symptoms to dystonia diagnosis were: cervical dystonia 5.2
(n = 278), blepharospasm 3.5 (n = 60), spasmodic dysphonia
4.0 (n = 10), limb dystonia 1.2 (n = 17), Meige syndrome 2.6
(n = 14), hemifacial spasm 3.2 (n = 112), generalized dystonia
8.0 (n = 8), oromandibular dystonia 5.0 (n = 8). 94% of patients
were treated with Botulinum Toxin Type A following their diag-
nosis with dystonia. CONCLUSION: The number of physicians
seen and length of time from onset to dystonia diagnosis is
substantial. Increased awareness of dystonia at the primary care
level may improve these rates.
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OBJECTIVE: Highly expensive disease modifying agents
(DMAs) were introduced in the 1990s to reduce the frequency of
relapse and to slow disease progression in patients with multiple
sclerosis (MS). However, the patterns of DMAs use remain
largely unknown. This study examines data from 2001–2005
population-based survey of MS patients to estimate duration of
DMA use and switching behavior, controlling for patient risk
factors. METHODS: We examined patterns of DMA use of 670
patients with relapsing remitting (RR) and secondary progressive
(SP) MS from the Sonya Slifka Longitudinal Multiple Sclerosis
Study. We generated Kaplan Meier covariate-adjusted estimates
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of survival functions, used Cox proportional hazard models, and
adjusted standard errors to account for survey design. RESULTS:
The duration of treatment was not different for the 3 interferons
and Copaxone, with 72% of patients continuing with the
therapy after 3 years, while 1.7% of patients on Novantrone
continued treatment after 3 years. Having SPMS increased the
risk of terminating DMA by 67% (p = 0.01) and having moder-
ate disability increased the risk by 77% (p = 0.001) compared
with less advanced disease. Older patients and those with longer
duration of MS were more likely to stay on DMA. Doctor’s
advice was the main reason for starting (47%) or stopping (20%)
DMA therapy, followed by side effects (10% and 27%, respec-
tively), and burden of drug administration (15% and 10%,
respectively). After Avonex, 37% of patients did not take any
DMA for at least 6 months, 17% switched to Copaxone and
15% to Rebif. After Betaseron, 51% stayed off DMAs while
19% switched to Copaxone. 37% of Copaxone users switched to
no DMA, and 16% switched to Avonex. CONCLUSION: The
majority of MS patients continued treatment for three years and
more. Consistent with the risk of cardiotoxicity associated with
long-term use, most patients discontinued Novantrone within
three years.
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OBJECTIVE: Generic substitution of antiepileptic drugs (AEDs)
may be problematic in patients receiving multiple generics
because variability in drug serum concentrations can induce
breakthrough seizures. To investigate clinical consequences of
generic substitution of one versus multiple generics of topiramate
(Topamax®). METHODS: Claims data of Régie de l’assurance-
maladie du Québec (RAMQ) from January 2006-October 2007
were used. Patients with epilepsy (ICD-9 345 or 780.3) treated
with topiramate (Canadian patent expired January 2006) were
selected. An open-cohort person-time design was used to classify
the observation period into mutually exclusive periods of brand,
single-generic, and multiple-generic use. One-year switching
rates of brand-to-generic and switchback-to-brand were com-
puted using Kaplan-Meier methodology. Medical resource utili-
zation (frequency per person–year) was compared among the
three periods using multivariate regressions adjusted for demo-
graphics, treatment characteristics and comorbidities. RESULTS:
A total of 948 patients were observed during 1105 person-years
(p/y) of brand use, 233 p/y of single-generic use, and 92 p/y
of multiple-generic use. Approximately 38% of brand users
switched to generic topiramate, of whom 14% switched back to
brand. Generic users received on average 1.4 generic versions,
with 23% taking two or more versions. Multiple-generic use was
associated with increased utilization of both AEDs and non-AED
drugs compared to brand (RR = 1.27, 95%CI = 1.24; 1.31) and
single-generic use (RR = 1.10, 95%CI = 1.06; 1.13) after covari-
ate adjustment. Multiple-generic use was associated with sig-
niﬁcantly higher hospitalization rate (0.48 vs. 0.83 visit/p/y,
RR = 1.65, 95%CI = 1.28; 2.13) and hospital length of stay (2.6
vs. 3.9 days/p/y, RR = 1.43, 95%CI = 1.27; 1.60), but the effect
was less pronounced in single-generic use (hospitalization:
RR = 1.08, 95%CI = 0.88; 1.34, length of stay: RR = 1.12,
95%CI = 1.03; 1.23). The risk of head injury or fracture was
5 times higher (HR = 5.43, 95%CI = 4.23; 6.97) following a
generic-to-generic switch compared to brand use. CONCLU-
SION: Multiple-generic substitution of topiramate was signiﬁ-
cantly associated with outcomes, such as hospitalizations,
fractures and injuries.
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OBJECTIVE: To examine if pharmacological treatment of
insomnia varied with patient’s gender, ethnic, or both.
METHODS: This was a cross-sectional study using data from
2004 National Ambulatory Medical Care Survey (NAMCS) by
National Center for Health Statistics. We identiﬁed visits at
which at least one frequently used insomnia prescription was
prescribed as deﬁned from the American Insomnia Association.
A series of population-based descriptive analyses were performed
to estimate the national weighted frequency of each drug.
Weighted chi-square statistics were used to compare insomnia
drugs uses by patients with different gender and ethnic charac-
teristics. To provide national estimates, all analyses incorporated
sample weights and standard errors corrections to adjust for the
complex sampling design employed by NAMCS. RESULTS: A
total of 910 million outpatient visits were estimated in the US. in
2004. A total of 24.98 million visits at least one insomnia pre-
scription was prescribed including 3.38 million visits(13.6%)
with FDA approved benzodiazepine receptor agonist; 8.5 million
visits(34.1%) with FDA approved non-benzodiazepine receptor
agonist; and 13.1 million visits (52.4%) with antipsychotic medi-
cations which is used for insomnia treatment without FDA
approved. Female received signiﬁcant more insomnia prescrip-
tion than male (16.4 mil. VS. 8.58 mil., P < 0.0001). Patients
who are Black and Hispanics received less insomnia prescription
than those who are white (P < 0.0001). CONCLUSION: The
study found a signiﬁcant gender and ethnic disparities in the use
of insomnia prescriptions especially to the use of related costly
non-benzodiazepine receptor agonist. The problems of access
barriers to health care for the minority population are still sig-
niﬁcant. The study also provided evidence that the non-FDA
approved prescription medications that were used signiﬁcantly
frequent to treat insomnia than currently approved agents. The
issue of off-label treatment for sleep has been raised concerns
about the adverse effects that develop during the insomnia treat-
ment and limit the efﬁcacy of these medications.
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OBJECTIVE: Since the early 1990s BoNT-A has been used as
prophylaxis treatment for headaches, including migraine. Evi-
dence suggests that this use is primarily in migraine patients who
are refractory to other prophylaxis treatments. This analysis aims
to evaluate the patterns of use and the characteristics of patients
treated with botulinum toxin type A (BoNT-A; BOTOX®; Aller-
gan, Inc, Irvine, CA) for migraine or headache. METHODS: A
retrospective, database claims analysis examining pharmacy and
medical claims from the Source Lx database (WoltersKluwer
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